Card image cap
Honeywell, AstraZeneca tie-up to develop novel respiratory inhalers

Honeywell, the American diversified technology group, has entered into a commercial partnership with AstraZeneca to develop and bring to market next-generation respiratory inhalers that use near-zero global warming potential (GWP) propellants to treat asthma and COPD. The propellant HFO-1234ze in a pMDI containing budesonide, glycopyrronium, formoterol fumarate, on which AstraZeneca recently completed Phase I clinical trials, would be developed in the said collaboration

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment